Treatment providers, policymakers, and others are seeking ways to reverse the tide of mortality and morbidity that has accompanied the opioid epidemic. There are evidence-based treatments for opioid use disorder (OUD), including medication-assisted treatment (MAT) using buprenorphine, methadone, and naltrexone. Research shows that retention in MAT results in better outcomes.
Prescription Drugs & Other Medical Products
Drugs and other medical products greatly impact human health and the health care system. ASPE conducts a variety of research in this area, including work related to medical product development and regulation; medical product markets, pricing and competition; prescription drug benefits and spending on medical products; medical product supply chains; and medical product safety.
Noteworthy
Reports
Displaying 81 - 90 of 178. 10 per page. Page 9.
Advanced SearchReport
Availability of Treatment for Opioid Use Disorder in Areas of High Foster Care Increases
Parental opioid use disorder (OUD) is a risk factor for the maltreatment of children and placement into foster care. Opioid agonist therapy (OAT) is an evidence-based treatment for OUD using medications such as methadone and buprenorphine. OAT can help parents enter recovery and reduce the risk of maltreatment, and potentially improve child welfare outcomes.
Addressing the Opioid Epidemic with Better Data: An Overview of HHS Priorities and Projects to Expand Data Capacity for Patient-Centered Outcomes Research on Opioids
This report builds on a workshop sponsored by ASPE, titled Addressing the Opioid Epidemic: Harnessing the Power of Data for Patient-Centered Research in December 2018, which showcased projects working to build the data infrastructure for patient-centered outcomes research around opioids.
Report to Congress
Report to Congress: Prescription Drug Pricing Report
The Secretary of Health and Human Services (HHS) has been directed to submit a drug pricing report containing information requested by the House Committee on Appropriations.
Report to Congress
Report to Congress: Prescription Drugs: Innovation, Spending, and Patient Access
This Report responded to a request from the House and Senate Committees on Appropriations.
Non-Fatal Opioid Overdose and Associated Health Outcomes: Final Summary Report
Non-fatal opioid overdose (NFOO) is a significant cause of opioid-related morbidity in the United States. As the number of NFOOs continues to grow, it is important to understand the short- and long-term consequences of NFOO.
Report
Psychosocial Supports in Medication-Assisted Treatment: Site Visit Findings and Conclusions
The purpose of this report is to gain a better understanding of the role and range of different models of psychosocial support in medication-assisted treatment for opioid use disorder.
ASPE Issue Brief
Optimal Utilization of Psychosocial Supports in Medication-Assisted Treatment for Opioid Use Disorder Issue Brief
Westat Printer Friendly Version in PDF Format (3 PDF pages)
Psychosocial Supports in Medication-Assisted Treatment: Recent Evidence and Current Practice
ABSTRACT
This report was included as Appendix B of "Psychosocial Supports in Medication-Assisted Treatment: Site Visit Findings and Conclusions." That report's purpose was to gain a better understanding of the role and range of different models of psychosocial support in medication-assisted treatment for opioid use disorder.
ASPE Issue Brief
Optimal Utilization of Psychosocial Supports in Medication-Assisted Treatment for Opioid Use Disorder Issue Brief
As the opioid epidemic has evolved into a national crisis, the need for treatment has increased greatly. Medication-assisted treatment (MAT) is a “whole-patient” approach to the treatment of opioid use disorder (OUD) that combines the use of medications and psychosocial supports, such as therapy, counseling, self-help groups, and case management.